Navigation Links
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Date:6/11/2008

endpoint was based on an intent-to-treat (ITT) analysis, which included all patients randomized in the study. However, three patients did not receive study drug but were included in the analysis as nonresponders. In the primary analysis of the combined group of patients receiving either golimumab 50 mg or 100 mg in combination with MTX, 38 percent (40 percent receiving 50 mg and 37 percent receiving 100 mg) achieved at least 50 percent improvement in signs and symptoms of RA (ACR 50) through week 24, compared with 29 percent of patients receiving placebo plus MTX (p=0.053 for the combined group, p=0.042 for 50 mg and p=0.177 for 100 mg). When the three patients who did not receive golimumab were excluded in a modified intent-to-treat (mITT) analysis, the results showed that 39 percent of patients in the combined golimumab plus MTX group (41 percent receiving 50 mg and 37 percent receiving 100 mg) achieved ACR 50, compared with 29 percent of patients receiving placebo plus MTX (p=0.049 for the combined group, p=0.038 for 50 mg and p=0.177 for 100 mg). Additionally, 62 percent of patients in the combined golimumab plus MTX group (62 percent for each dose group) achieved ACR 20, compared with 49 percent receiving placebo plus MTX (p=0.011 for the combined group and p=0.028 for each dose group).

"These data show that treatment with golimumab induces an important depth of response, improving multiple aspects of rheumatoid arthritis and leading to significant decreases in disease activity," said Roy Fleischmann, M.D., Clinical Professor, Department of Internal Medicine at the University of Texas Southwestern Medical Center; Chief, Division of Rheumatology at St. Paul University Hospital in Dallas, Texas and lead study investigator. "Golimumab, which is an anti-TNF therapy, is a promising treatment option for multiple patient populations with this chronic and potentially debilitating inflammatory disease."

Also at week 24, patients receiving golimumab plus MT
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... MUMBAI , November 18, 2014 ... thorough knowledge of the overall new requirements of application ... China but also provides the guidance ... approval for your products entry into the Chinese medical ... Chinese medical device market is one of segment market ...
(Date:11/18/2014)... , Nov. 18, 2014  Cardica, Inc. ... the Cardica Board has approved management,s recommendation to ... launch of the MicroCutter XCHANGE® 30 surgical stapler ... commercial launch.  As a result, Cardica has temporarily ... withdrawing its latest iteration of the MicroCutter XCHANGE ...
(Date:11/18/2014)... Nov. 18, 2014  Palatin Technologies, Inc. ... targeted, receptor-specific peptide therapeutics for the treatment ... and commercial potential, today announced results for ... Recent Highlights , ... , €7.5M ($9.8M) total upfront payment - ...
Breaking Medicine Technology:Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation in China (2014 Edition) 2Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation in China (2014 Edition) 3Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation in China (2014 Edition) 4Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation in China (2014 Edition) 5Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation in China (2014 Edition) 6Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation in China (2014 Edition) 7Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation in China (2014 Edition) 8Cardica Announces Shift In Focus 2Cardica Announces Shift In Focus 3Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014 2Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014 3Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014 4Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014 5Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014 6Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014 7
... Conference: February 13-16, 2012 ,Exposition: February ... Organizers of the Medical Design and Manufacturing (MD&M) West ... be held at the Anaheim Convention Center, February 13-16, ... event in the United States dedicated to medical design ...
... N.C., Jan. 20, 2012  As the pace of ... has become challenging for the biopharma industry to ... messages. Consumers, key opinion leaders, payers ... and biotech companies reach out to with marketing ...
Cached Medicine Technology:MD&M West 2012 to Feature Twenty Collocated Conferences 2Utilizing Marketing Innovations to Engage with Customer Groups that are Key to the Pharmaceutical Industry 2
(Date:11/18/2014)... 18, 2014 Medicationdiscountcard.com's ... adding to the company's reputation for helping consumers ... blog has to offer at http://blog.medicationdiscountcard.com/ . ... information concerning the Affordable Care Act and the ... inform the public about a variety of prescription ...
(Date:11/18/2014)... screening for heart disease isn,t effective for people with ... risk for a heart attack, according to a new ... prevent heart attacks or help patients avoid being admitted ... occurs when the heart doesn,t receive enough oxygen-carrying blood). ... to manage risks for heart-related complications, the study authors ...
(Date:11/18/2014)... 2014 Financing for Development Corp. ... financing for international development, has announced the first ... six Directors: Mr. John Skibiak of the Reproductive ... Millennium Challenge Corporation, Mr. Pape Gaye of IntraHealth ... Mr. Aron Betru of Financing for Development, and ...
(Date:11/18/2014)... Virginia (PRWEB) November 18, 2014 Sometimes ... frustrating situations with print devices like unforeseen error messages ... they don't have time to find another printer and ... issue. The IT department is likely tied up with ... , That’s where Electronic Systems, Inc. ...
(Date:11/18/2014)... Recently, Wigsbuy has introduced its newest collection of ... greatly discounted prices now, up to 85% off. , Wigsbuy ... products, offering many real and synthetic hair products. In order ... uses high quality materials to make its hair wigs, which ... , “We are offering a full line of human ...
Breaking Medicine News(10 mins):Health News:Medicationdiscountcard.com Building Virtual Library of Resources to Help Consumers Navigate Healthcare Landscape 2Health News:Study Finds No Added Benefit From Routine Heart Scans for Diabetics 2Health News:Study Finds No Added Benefit From Routine Heart Scans for Diabetics 3Health News:Financing for Development Corp. (F4D) Announces Board of Directors 2Health News:Financing for Development Corp. (F4D) Announces Board of Directors 3Health News:Financing for Development Corp. (F4D) Announces Board of Directors 4Health News:Electronic Systems, providing Managed Print Services (MPS) in Virginia & Outer Banks North Carolina 2Health News:It Is The Most Wonderful Time To Buy Full Lace Wigs At Wigsbuy.com 2
... Team suggests screening spares patients lifetime of problems , , ... lifetime of problems with getting a good night,s sleep ... attention-deficit hyperactivity disorder (ADHD). , The study of 281 ... with ADHD, found that regardless of the severity of ...
... Takes Place on the Eve of the 8th Annual National ... for 14 straight years, the teen birth rate in the ... in Washington, DC sponsored by The National Campaign to Prevent ... rate is increasing and will explore ways to try to ...
... the Product Offering of Avalign Technologies, Inc.LAKE ... Partners ("RoundTable"), an operating-oriented private equity firm ... today that its portfolio company, Avalign ... of instruments, implants, and delivery systems to ...
... resulting from high-energy blasts is one possible underlying causeROSEMONT, ... who are wounded in combat as the result of ... likely to develop an abnormality known as heterotopic ossification. ... such as muscle located near a fracture or other ...
... LIFE Urges Americans to Think About Income Protection, Offers Tips ... The results of a new survey show the historic ... investments -- and as a consequence, they are more vulnerable ... become sick or hurt and couldn,t work. According to the ...
... and Afghanistan ... To help ease the transition and readjustment challenges facing Iraq and ... America (IAVA) joined the Ad Council today to launch a new ... Campaign. Launched on Veterans Day 2008, the first series of ads ...
Cached Medicine News:Health News:Treating Sleep Disorders May Ease ADHD Symptoms 2Health News:Forum Explores Solutions to the Rise in the Teen Birth Rate 2Health News:Forum Explores Solutions to the Rise in the Teen Birth Rate 3Health News:RoundTable Healthcare Partners Completes Portfolio Company Add-On Acquisition 2Health News:RoundTable Healthcare Partners Completes Portfolio Company Add-On Acquisition 3Health News:Injured Marines at Risk for Abnormal Bone Growth 2Health News:Injured Marines at Risk for Abnormal Bone Growth 3Health News:Hit Hard by the Economy, Americans Risk Knockout Without Disability Insurance 2Health News:Hit Hard by the Economy, Americans Risk Knockout Without Disability Insurance 3Health News:Hit Hard by the Economy, Americans Risk Knockout Without Disability Insurance 4Health News:Video: IAVA and Ad Council Build on Success of Groundbreaking Veterans Campaign with New Friends and Family Element 2Health News:Video: IAVA and Ad Council Build on Success of Groundbreaking Veterans Campaign with New Friends and Family Element 3Health News:Video: IAVA and Ad Council Build on Success of Groundbreaking Veterans Campaign with New Friends and Family Element 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: